ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma

ClinicalTrials.gov ID: NCT02181634

Public ClinicalTrials.gov record NCT02181634. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 9:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Institutional, Single Arm, Two-Stage Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma

Study identification

NCT ID
NCT02181634
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
PrECOG, LLC.
Other
Enrollment
74 participants

Conditions and interventions

Interventions

  • Nab-Paclitaxel and Gemcitabine Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 8, 2014
Primary completion
Sep 23, 2016
Completion
Sep 30, 2017
Last update posted
Oct 2, 2018

2014 – 2017

United States locations

U.S. sites
24
U.S. states
13
U.S. cities
20
Facility City State ZIP Site status
Colorado Cancer Research Program Denver Colorado 80222
Northwestern University Chicago Illinois 60611
Advocate Christ Medical Center Oak Lawn Illinois 60453
Siouxland Hematology-Oncology Associates Sioux City Iowa 51101
Ochsner Medical Center New Orleans Louisiana 70121
Tufts Medical Center Boston Massachusetts 02111
University Massachusetts Memorial Medical Center Worcester Massachusetts 01655
St. Joseph Mercy Health System Ann Arbor Michigan 48106-0995
University of Michigan Health System Ann Arbor Michigan 48109
University of Michigan Medical Center Ann Arbor Michigan 48109
Metro Minnesota CCOP Saint Louis Park Minnesota 55416
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey 08901
Mount Sinai Hospital New York New York 10029
University of Rochester Medical Center Rochester New York 14642
Montefiore Medical Center The Bronx New York 10461
University of Pennsylvania, Abramson Cancer Center Philadelphia Pennsylvania 19104
University of Pennsylvania; Abramson Cancer Center at Presbyterian Medical Center Philadelphia Pennsylvania 19104
Fox Chase Cancer Center Philadelphia Pennsylvania 19111
University of Tennessee Medical Center Knoxville Tennessee 37920
Vanderbilt University/Ingram Cancer Center Nashville Tennessee 37232
University of Texas Southwestern Medical Center Dallas Texas 75390
Gundersen Health System La Crosse Wisconsin 54601
University of Wisconsin-Madison Madison Wisconsin 53792
Aurora Cancer Care Wauwatosa Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02181634, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 2, 2018 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02181634 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →